AUGMENTIN ES SUMMARY
AUGMENTIN ES-600 Powder for Oral Suspension is an oral antibacterial combination consisting of the semisynthetic antibiotic amoxicillin and the β-lactamase inhibitor, clavulanate potassium (the potassium salt of clavulanic acid). Amoxicillin is an analog of ampicillin, derived from the basic penicillin nucleus, 6-aminopenicillanic acid.
AUGMENTIN ES-600 Powder for Oral Suspension is indicated for the treatment of pediatric patients with recurrent or persistent acute otitis media due to S. pneumoniae
(penicillin MICs ≤ 2 mcg/mL), H.
influenzae (including β-lactamase–producing strains), or
M. catarrhalis (including
β-lactamase–producing strains) characterized by the following risk
factors:
- antibiotic exposure for acute otitis media within the preceding 3 months, and either of the following:
- daycare attendance
[See CLINICAL PHARMACOLOGY, Microbiology.]
NOTE: Acute otitis media due to S. pneumoniae alone can be treated with
amoxicillin. AUGMENTIN ES-600 Powder for Oral Suspension is not
indicated for the treatment of acute otitis media due to S. pneumoniae with penicillin MIC ≥ 4 mcg/mL.
Therapy may be instituted prior to obtaining the results from
bacteriological studies when there is reason to believe the infection may
involve both S. pneumoniae (penicillin
MIC ≤ 2 mcg/mL) and the β-lactamase–producing organisms listed
above.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of AUGMENTIN ES-600 Powder for Oral Suspension and other antibacterial drugs, AUGMENTIN ES-600 Powder for Oral Suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
|
|
NEWS HIGHLIGHTS
Published Studies Related to Augmentin ES (Amoxicillin / Clavulanate)
Response of feline eosinophilic plaques and lip ulcers to amoxicillin
trihydrate-clavulanate potassium therapy: a randomized, double-blind
placebo-controlled prospective study. [2012] In this study, we evaluated the treatment of feline eosinophilic plaques and lip
ulcers with amoxicillin trihydrate-potassium clavulanate (Clavamox(®); Pfizer
Animal Health). Nineteen cats with clinical and cytological findings consistent
with eosinophilic plaques and/or lip ulcers were enrolled...
Single-dose extended-release azithromycin versus a 10-day regimen of amoxicillin/clavulanate for the treatment of children with acute otitis media. [2011.04] OBJECTIVES: A randomized, double-blind, double-dummy, multicenter international study was conducted to assess the clinical and bacteriologic response, safety, and compliance of a single 60-mg/kg dose of azithromycin extended-release (ER) versus a 10-day regimen of amoxicillin/clavulanate 90/6.4 mg/kg per day in children with acute otitis media at high risk of persistent or recurrent middle ear infection... CONCLUSIONS: A single 60-mg/kg dose of azithromycin ER provides near equivalent effectiveness to a 10-day regimen of amoxicillin/clavulanate 90/6.4 mg/kg per day in the treatment of children with acute otitis media. Copyright (c) 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Amoxicillin/clavulanic acid-warfarin drug interaction: a randomized controlled trial. [2011.02] AIMS: To investigate whether an interaction exists between amoxicillin/clavulanic acid (amoxiclav) and warfarin in patients treated with stable oral anticoagulant therapy... CONCLUSION: Amoxiclav did not modify anticoagulation in patients treated with stable warfarin therapy and without infection. (c) 2011 The Authors. British Journal of Clinical Pharmacology (c) 2011 The British Pharmacological Society.
Azithromycin extended release vs amoxicillin/clavulanate: symptom resolution in acute sinusitis. [2010.01] OBJECTIVE: The aim of the study was to compare early symptom resolution with a single 2-g dose of azithromycin extended release or 10 days of amoxicillin/clavulanate 875 mg/125 mg every 12 hours in patients with acute sinusitis... CONCLUSIONS: More patients randomized to azithromycin extended release experienced symptom resolution at day 5 than those randomized to amoxicillin/clavulanate, without experiencing differences in second antibiotic use at 28 days.
Fosfomycin in a single dose versus a 7-day course of amoxicillin-clavulanate for the treatment of asymptomatic bacteriuria during pregnancy. [2009.12] The purpose of this paper was to compare the efficacy of a single dose of 3 g of fosfomycin to that of a 7-day regimen of amoxicillin-clavulanate in the treatment of asymptomatic bacteriuria during pregnancy. A randomised, prospective, interventional, analytical, longitudinal study was undertaken, in which the efficacy of two antibiotic regimens (one short and the other long) in the treatment of pregnant women with asymptomatic bacteriuria is compared...
Clinical Trials Related to Augmentin ES (Amoxicillin / Clavulanate)
Amoxicillin-Clavulanic Acid 400 mg-57 mg Chewable Tablets Under Fasting Conditions [Completed]
The objective of this study is to compare the rate and extent of absorption of
amoxicillin-clavulanic acid 400 mg-57 mg chewable tablets (test) versus Augmentin®
(reference) administered as 1 x 400 mg-57 mg chewable tablet under fasting conditions.
AUGMENTIN 1gm In Skin And Soft Tissue Infection [Completed]
Amoxicillin-Clavulanic Acid 400 mg-57 mg Chewable Tablets Under Non-Fasting Conditions [Completed]
The objective of this study is to compare the rate and extent of absorption of
amoxicillin-clavulanic acid 400 mg-57 mg chewable tablets (test) versus Augmentin®
(reference) administered as 1 x 400 mg-57 mg chewable tablet under fed conditions.
Amoxicillin-clavulanate in Treating Acute Otitis Media Evaluated by Daily Tympanometry [Completed]
The purpose of the study is to assess the efficacy of amoxicillin-clavulanate in treating
acute otitis media in children. The primary end point is time to disappearance of middle ear
effusion which monitored by daily tympanometry performed by families and study physicians.
Bioequivalence Study of an Amoxicillin-Clavulanic [Completed]
The objective of this study was to confirm if two formulations of amoxicillin and clavulanic
acid (suspension) are bioequivalent.
Test product was AUGMENTIN 12H (400 mg Amoxicillin and 57 mg Clavulanic acid/ 5 ml; Glaxo
Wellcome France) and reference product AUGMENTIN 12H (400 mg Amoxicillin and 57 mg
Clavulanic acid/ 5 ml; GlaxoSmithKline Mexico). The single dosage was 10 ml of suspension.
The study was prospective, open-label, randomized, crossover, single dose, with 02
treatments, 02 sequences and 02 periods, under fasting conditions.
The population was composed of 35 healthy volunteers, both genders, adults between 18-50
years.
The comparative bioavailability of the two formulations was evaluated based in statistical
comparisons of relevant pharmacokinetic parameters, obtained from data of drug
concentrations in blood.
|
|
Page last updated: 2013-02-10
|